@article {Marconi2021.04.30.21255934, author = {Vincent C. Marconi and Athimalaipet V. Ramanan and Stephanie de Bono and Cynthia E. Kartman and Venkatesh Krishnan and Ran Liao and Maria Lucia B. Piruzeli and Jason D. Goldman and Jorge Alatorre-Alexander and Rita de Cassia Pellegrini and Vicente Estrada and Mousumi Som and Anabela Cardoso and Sujatro Chakladar and Brenda Crowe and Paulo Reis and Xin Zhang and David H. Adams and E. Wesley Ely and on behalf of the COV-BARRIER Study Group}, title = {Efficacy and safety of baricitinib in patients with COVID-19 infection: Results from the randomised, double-blind, placebo-controlled, parallel-group COV-BARRIER phase 3 trial}, elocation-id = {2021.04.30.21255934}, year = {2021}, doi = {10.1101/2021.04.30.21255934}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background The efficacy and safety of baricitinib, an oral selective Janus kinase 1/2 inhibitor, in addition to standard of care (SOC) in hospitalised adults with COVID-19 is unknown.Methods In this phase 3, global, double-blind, randomised, placebo-controlled trial, participants were enrolled from 101 centres across 12 countries in Asia, Europe, North America, and South America (ClinicalTrials.gov NCT04421027). Hospitalised adults with COVID-19 receiving SOC were randomly assigned (1:1) to once-daily baricitinib 4-mg or placebo for up to 14 days. SOC included systemic corticosteroids in 79{\textperiodcentered}3\% of participants (dexamethasone \~{}90\%). The composite primary endpoint was the proportion who progressed to high-flow oxygen, non-invasive ventilation, invasive mechanical ventilation, or death by day 28. All-cause mortality by days 28 and 60 were key secondary and exploratory endpoints, respectively. Efficacy and safety analyses included the intent-to-treat and safety populations, respectively.Findings Between June 11, 2020 and January 15, 2021, 1525 participants were randomly assigned to baricitinib 4-mg (n=764) or matched placebo (n=761). Overall, 27{\textperiodcentered}8\% of participants receiving baricitinib vs 30{\textperiodcentered}5\% receiving placebo progressed (primary endpoint, odds ratio 0{\textperiodcentered}85, 95\% CI 0{\textperiodcentered}67-1{\textperiodcentered}08; p=0{\textperiodcentered}18). The 28-day all-cause mortality was 8{\textperiodcentered}1\% (n=62) for baricitinib and 13{\textperiodcentered}1\% (n=100) for placebo, corresponding to a 38{\textperiodcentered}2\% reduction in mortality (hazard ratio [HR] 0{\textperiodcentered}57, 95\% CI 0{\textperiodcentered}41-0{\textperiodcentered}78; nominal p=0{\textperiodcentered}0018). The 60-day all-cause mortality was 10{\textperiodcentered}3\% (n=79) for baricitinib and 15{\textperiodcentered}2\% (n=116) for placebo (HR 0{\textperiodcentered}62, 95\% CI 0{\textperiodcentered}47-0{\textperiodcentered}83; p=0{\textperiodcentered}0050). Frequency of serious adverse events (14{\textperiodcentered}7\% [n=110] vs 18{\textperiodcentered}0\% [n=135]), serious infections (8{\textperiodcentered}5\% [n=64] vs 9{\textperiodcentered}8\% [n=74]), and venous thromboembolic events (2{\textperiodcentered}7\% [n=20] vs 2{\textperiodcentered}5\% [n=19]) was similar between baricitinib and placebo, respectively.Interpretation While reduction of disease progression did not achieve statistical significance, treatment with baricitinib in addition to SOC (including dexamethasone) significantly reduced mortality, with a similar safety profile to SOC, in hospitalised COVID-19 participants.Funding Eli Lilly and Company.Evidence before this study We searched PubMed using the terms {\textquotedblleft}COVID-19{\textquotedblright}, {\textquotedblleft}SARS-CoV-2{\textquotedblright}, {\textquotedblleft}treatment{\textquotedblright}, {\textquotedblleft}baricitinib{\textquotedblright} and {\textquotedblleft}JAK inhibitor{\textquotedblright} for articles in English published up to April 31, 2020, regardless of article type. We considered previous and current clinical trials of investigational medications in COVID-19, as well as previous clinical trials of the Janus kinase (JAK)1 and JAK2 inhibitor, baricitinib, before undertaking this study. At the time the COV-BARRIER study was designed, there were no approved therapies for the treatment of COVID-19. Management of COVID-19 was supportive, and limited phase 3 randomised placebo-controlled studies had been completed. Limited phase 2 and 3 data on the antimalarial hydroxychloroquine and protease inhibitor lopinavir/ritonavir were available, and trials investigating the use of the antiviral remdesivir were ongoing. Baricitinib{\textquoteright}s mechanism of action as a JAK1 and JAK2 inhibitor was identified as a potential intervention for the treatment of COVID-19 given its known anti-cytokine properties and potential for targeting host proteins for its antiviral mechanism. Additionally, early case series evaluating the efficacy and safety of baricitinib in the hospitalised patient population supported further evaluation of baricitinib as a potential treatment option for hospitalised patients with COVID-19. While COV-BARRIER was enrolling, ACTT-2, a phase 3 study evaluating baricitinib plus remdesivir was completed showing that baricitinib added to remdesivir improved time to recovery and other outcomes.Added value of this study This was the first phase 3 study to evaluate baricitinib in addition to the current standard of care (SOC) and included antivirals, anticoagulants, and corticosteroids. After the earliest publication of the RECOVERY study in June 2020, the treatment of hospitalised patients with COVID-19 changed with the adoption of dexamethasone as SOC. As a result of its design, COV-BARRIER became the first trial to evaluate the benefit/risk of baricitinib when added to the most current SOC (dexamethasone) in these patients. This was a randomised, double-blind, placebo-controlled trial conducted globally in regions with high COVID-19 hospitalisation rates. The reduction in the composite primary endpoint of progression to non-invasive ventilation, high flow oxygen, invasive mechanical ventilation, or death for baricitinib plus SOC (including dexamethasone) compared to placebo plus SOC did not reach statistical significance. However, in a pre-specified key secondary endpoint, treatment with baricitinib reduced 28-day all-cause mortality by 38{\textperiodcentered}2\% compared to placebo (HR 0{\textperiodcentered}57, 95\% CI 0{\textperiodcentered}41-0{\textperiodcentered}78; nominal p=0{\textperiodcentered}0018); one additional death was prevented per 20 baricitinib-treated participants. The reduction of all-cause mortality with baricitinib was maintained by day 60 in an exploratory analysis. The frequency of serious adverse events, serious infections, and venous thromboembolic events was similar between baricitinib and placebo, respectively.Implications of all the available evidence In this phase 3 trial, baricitinib given in addition to SOC (which predominantly included dexamethasone) did not reduce a composite endpoint of disease progression, but showed a strong effect on reducing mortality by 28 days, an effect which was maintained by 60 days. In the ACTT-2 study, baricitinib further reduced time to recovery above the background use of remdesivir. Taken together, these findings suggest that baricitinib has synergistic effects to other SOC treatment modalities including remdesivir and dexamethasone. Based on all available evidence, baricitinib is a potentially effective oral treatment option to decrease mortality in hospitalised patients with COVID-19.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form and declare: Vincent C. Marconi received research grants from CDC, Gilead Sciences, NIH, VA, and ViiV, received honoraria from Eli Lilly and Company, served as an advisory board member for Eli Lilly and Company and Novartis and participated as a study section chair for the NIH. Athimalaipet V. Ramanan received research grants from Eli Lilly and Company, served as a speaker and/or consultant for AbbVie, Eli Lilly and Company, Novartis, Pfizer, Roche, Sobi and UCB. Stephanie de Bono, Cynthia E. Kartman, Venkatesh Krishnan, Ran Liao, Maria Lucia B. Piruzeli, Anabela Cardoso, Sujatro Chakladar, Brenda Crowe, Paulo Reis, Xin Zhang, and David H. Adams are employees and shareholders of Eli Lilly and Company. Jason D. Goldman received research support from Eli Lilly and Company, Regeneron Pharmaceuticals, and Gilead Sciences, grants from Eurofins Viracor, the Biomedical Advanced Research and Development Authority (administered by Merck), speaker fees from Gilead Sciences, Mylan Pharmaceuticals and advisory board fees from Gilead Sciences. Rita de Cassia Pellegrini has no conflicts to disclose. Jorge Alatorre-Alexander served as a speaker and scientific advisor for Astra Zeneca, Boehringer Ingelheim, BMS, Eli Lilly and Company, Foundation Medicine, Novartis, MSD, Roche and Takeda. Vicente Estrada received a research grant from Eli Lilly and Company. Mousumi Som received research grants from Eli Lilly and Company, NIAID, Novartis and served as a board member for NBOME, Osteopathic Founders Foundation and COGMED. E. Wesley Ely received research grants from CDC, NIH and VA, and served as an unpaid consultant for Eli Lilly and Company.Clinical TrialNCT04421027Funding StatementThis study was funded by Eli Lilly and Company, under license from Incyte Corporation. All authors received manuscript preparation support from Eli Lilly and Company. Stephanie de Bono, Cynthia E. Kartman, Venkatesh Krishnan, Ran Liao, Maria Lucia B. Piruzeli, Anabela Cardoso, Sujatro Chakladar, Brenda Crowe, Paulo Reis, Xin Zhang, and David H. Adams are Employees and stockholders of Eli Lilly and Company. Jason D. Goldman, Jorge Alatorre-Alexander, Rita de Cassia Pellegrini, Vicente Estrada, and Mousumi Som or their institutions were paid as study investigators. Athimalaipet V. Ramanan is a paid advisor. Vincent C. Marconi and E. Wesley Ely received no funding for this research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted in accordance with ethical principles of the Declaration of Helsinki and Good Clinical Practice guidelines. All sites received approval from the authorized institutional review board (See {\textquoteright}COV-BARRIER_IRB_Report.docx{\textquoteright}). All patients (or legally authorized representatives) provided informed consent. An independent, external data monitoring committee oversaw the study and evaluated unblinded interim data for efficacy, futility and safety analyses. An independent, blinded, clinical event committee adjudicated potential VTEs and deaths.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesEli Lilly and Company provides access to all individual participant data collected during the trial, after anonymization, with the exception of pharmacokinetic or genetic data. Data are available to request 6 months after the indication studied has been approved in the US and EU and after the trial is completed, whichever is later. No expiration date of data requests is currently set once data are made available. Access is provided after a proposal has been approved by an independent review committee identified for this purpose and after receipt of a signed data sharing agreement. Data and documents, including the study protocol, statistical analysis plan, clinical study report, blank or annotated case report forms, will be provided in a secure data sharing environment. For details on submitting a request, see the instructions provided at www.vivli.org.}, URL = {https://www.medrxiv.org/content/early/2021/05/30/2021.04.30.21255934}, eprint = {https://www.medrxiv.org/content/early/2021/05/30/2021.04.30.21255934.full.pdf}, journal = {medRxiv} }